These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1812362)

  • 1. Paramagnetic iron (III) MRI contrast agents.
    White DL
    Magn Reson Med; 1991 Dec; 22(2):309-12. PubMed ID: 1812362
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatic transport of magnetic resonance imaging contrast agents. Ferrioxamine B derivatives.
    White DL; Eason RG; Alkire AL; Price DC; Hoener BA; Milco LA; Keen RE; Barnhart JL
    Invest Radiol; 1991 Nov; 26 Suppl 1():S146-7; discussion S150-5. PubMed ID: 1808112
    [No Abstract]   [Full Text] [Related]  

  • 3. Synthesis of two 3,5-disubstituted sulfonamide catechol ligands and evaluation of their iron(III) complexes for use as MRI contrast agents.
    Schwert DD; Richardson N; Ji G; Radüchel B; Ebert W; Heffner PE; Keck R; Davies JA
    J Med Chem; 2005 Nov; 48(23):7482-5. PubMed ID: 16279808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ferrioxamine as a magnetic resonance contrast agent. Preclinical studies and phase I and II human clinical trials.
    Worah D; Berger AE; Burnett KR; Cockrill HH; Kanal E; Kendall C; Leese PT; Lyons KP; Ross E; Wolf GL
    Invest Radiol; 1988 Sep; 23 Suppl 1():S281-5. PubMed ID: 3058632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrast-enhanced magnetic resonance imaging of the liver.
    Van Beers B
    J Belge Radiol; 1997 Dec; 80(6):322. PubMed ID: 9479919
    [No Abstract]   [Full Text] [Related]  

  • 6. Paramagnetic pharmaceuticals for magnetic resonance imaging.
    Wesbey GE; Engelstad BL; Brasch RC
    Physiol Chem Phys Med NMR; 1984; 16(2):145-55. PubMed ID: 6095341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using radiotracers to characterize magnetic resonance imaging contrast agents.
    Tweedle MF
    Invest Radiol; 2002 Mar; 37(3):107-13. PubMed ID: 11882789
    [No Abstract]   [Full Text] [Related]  

  • 8. Dual contrast magnetic resonance imaging tracking of iron-labeled cells in vivo.
    Wu S; Zhang L; Zhong J; Zhang Z
    Cytotherapy; 2010 Nov; 12(7):859-69. PubMed ID: 20184501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metal chelates as urographic contrast agents for magnetic resonance imaging. A comparative study.
    Marotti M; Schmiedl U; White D; Ramos E; Johnson T; Engelstad B
    Rofo; 1987 Jan; 146(1):89-93. PubMed ID: 3027795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron-EHPG as an hepatobiliary MR contrast agent: initial imaging and biodistribution studies.
    Lauffer RB; Greif WL; Stark DD; Vincent AC; Saini S; Wedeen VJ; Brady TJ
    J Comput Assist Tomogr; 1985; 9(3):431-8. PubMed ID: 3989032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chitosan-triphosphate nanoparticles for encapsulation of super-paramagnetic iron oxide as an MRI contrast agent.
    Sanjai C; Kothan S; Gonil P; Saesoo S; Sajomsang W
    Carbohydr Polym; 2014 Apr; 104():231-7. PubMed ID: 24607182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical use of contrast media in magnetic resonance imaging.
    Bydder GM
    Br J Hosp Med; 1990 Feb; 43(2):149-52. PubMed ID: 2178714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fe(III)-EHPG and Fe(III)-5-Br-EHPG as contrast agents in MRI: an animal study.
    Liu GC; Wang YM; Jaw TS; Chen HM; Sheu RS
    J Formos Med Assoc; 1993 Apr; 92(4):359-66. PubMed ID: 8104585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-Molecular-Weight Iron Chelates May Be an Alternative to Gadolinium-based Contrast Agents for T1-weighted Contrast-enhanced MR Imaging.
    Boehm-Sturm P; Haeckel A; Hauptmann R; Mueller S; Kuhl CK; Schellenberger EA
    Radiology; 2018 Feb; 286(2):537-546. PubMed ID: 28880786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron Oxide Nanoparticle Based Contrast Agents for Magnetic Resonance Imaging.
    Shen Z; Wu A; Chen X
    Mol Pharm; 2017 May; 14(5):1352-1364. PubMed ID: 27776215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents.
    Lee N; Hyeon T
    Chem Soc Rev; 2012 Apr; 41(7):2575-89. PubMed ID: 22138852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Albumin binding of paramagnetic hepatobiliary contrast agents: enhancement of outer sphere relaxivity.
    Lauffer RB; Betteridge DR; Padmanabhan S; Brady TJ
    Int J Rad Appl Instrum B; 1988; 15(1):45-6. PubMed ID: 3350695
    [No Abstract]   [Full Text] [Related]  

  • 18. Physiological principles for the design of hepatic contrast agents.
    Stark DD
    Magn Reson Med; 1991 Dec; 22(2):324-8; discussion 343-6. PubMed ID: 1812365
    [No Abstract]   [Full Text] [Related]  

  • 19. Biodistribution and pharmacokinetic studies of SPION using particle electron paramagnetic resonance, MRI and ICP-MS.
    Gobbo OL; Wetterling F; Vaes P; Teughels S; Markos F; Edge D; Shortt CM; Crosbie-Staunton K; Radomski MW; Volkov Y; Prina-Mello A
    Nanomedicine (Lond); 2015; 10(11):1751-60. PubMed ID: 26080697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrast agents: magnetic resonance.
    Burtea C; Laurent S; Vander Elst L; Muller RN
    Handb Exp Pharmacol; 2008; (185 Pt 1):135-65. PubMed ID: 18626802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.